Filing Flows › Recursion Pharmaceuticals (RXRX) › Q4 2025
Recursion Pharmaceuticals (RXRX) Q4 2025 earnings results (fourth quarter 2025)
10-K filed Feb 25, 2026
Recursion Pharmaceuticals (RXRX) reported revenue of $35.5M for the fourth quarter 2025 (Q4 2025), +682% from a year earlier and +587% from the quarter before. Operating margin was -304.8%, net loss $108M (304.2% of revenue).
Recursion Pharmaceuticals, Q4 2025: revenue $35.5M (+682% year over year), operating margin -304.8%, net loss $108M, operating cash flow −$46.1M. The chart follows the revenue to costs, profit and cash.
| Q4 2025 | Amount | Q/Q | Y/Y |
|---|---|---|---|
| Revenue | $35.5M | +587% | +682% |
| Operating profit | −$108M | — | — |
| Net earnings | −$108M | — | — |
| Operating cash flow | −$46.1M | — | — |
What changed
Revenue was $35.5M in Q4 2025, up 682% year over year and up 587% from the previous quarter. Operating revenue was the largest line at 99% of revenue.
Operating costs exceeded revenue by $108.3M, an operating margin of -304.8%. Total costs fell 24% while revenue rose 682%. The fastest-growing cost line was Cost of revenue (+12%). The quarter ended with a net loss of $108.1M, narrower than the previous quarter's $162.3M loss.
Operating cash flow was −$46.1M. Non-cash charges added back $19.5M of depreciation and amortization and $23.8M of share-based compensation. Working capital and other items added $18.8M. Capital expenditures of $1.2M exceeded it, leaving free cash flow of −$47.3M.
Questions
What was Recursion Pharmaceuticals' revenue in the fourth quarter 2025?
Recursion Pharmaceuticals (RXRX) reported revenue of $35.5M for the fourth quarter 2025 (Q4 2025), +682% from a year earlier and +587% from the quarter before.
Was Recursion Pharmaceuticals profitable in the fourth quarter 2025?
Operating loss was $108M (-304.8% of revenue) and net loss $108M.